Related Experiment Videos

[Inflammation and chronic heart failure. The role of statins]

E M Ozova, G K Kiiakbaev, Zh D Kobalava

    Kardiologiia
    |April 12, 2007
    PubMed

    Insights

    Statins, cholesterol-lowering drugs, show potential anti-inflammatory benefits for chronic heart failure (CHF) patients. Ongoing trials will determine their safety and effectiveness in treating this condition.

    Area of Science:

    • Cardiology
    • Immunology
    • Pharmacology

    Context:

    • Immune inflammation plays a key role in chronic heart failure (CHF) pathogenesis.
    • Proinflammatory cytokines, endothelial dysfunction, and oxidative stress negatively impact CHF patient outcomes.
    • Previous attempts using tumor necrosis factor-alpha (TNFa) inhibitors failed to improve CHF treatment efficacy.

    Purpose:

    • To explore the potential therapeutic role of statins in managing chronic heart failure (CHF).
    • To evaluate the anti-inflammatory properties of statins as a treatment strategy for CHF.
    • To address theoretical concerns regarding statin use in CHF patients, particularly the cholesterol-mortality paradox.

    Summary:

    • Statins, known for lipid-lowering, possess pleiotropic anti-inflammatory actions relevant to CHF.
    • Despite epidemiological data suggesting a reverse cholesterol-mortality relationship in CHF, preclinical and clinical evidence supports statin investigation.
    • The safety and feasibility of statins in CHF will be clarified by ongoing randomized trials like GISSI-HF and CORONA.

    Impact:

    • Statins may offer a novel therapeutic avenue for CHF by targeting underlying inflammation.
    • Resolving the debate on statin use could significantly alter clinical practice guidelines for CHF management.
    • Successful application of statins could improve clinico-hemodynamic parameters and prognosis for CHF patients.

    Related Concept Videos

    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    Heart Failure I: Introduction01:27

    Heart Failure I: Introduction

    Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
    Inflammation01:38

    Inflammation

    Overview
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Myocarditis I: Introduction01:21

    Myocarditis I: Introduction

    Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...